.-1 Targeted Cancer Therapy: History and Development of Immunotoxins

.-2 Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective

.-3 Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins

.-4 Cell Signaling and Resistance to Immunotoxins

.-5 Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms

.-6 Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins

.-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy

.-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins

.-9 Therapeutic Impact of Immune Responses in Cancer

.-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy

.-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins

.-9 Therapeutic Impact of Immune Responses in Cancer

.-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy

.-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins

.-9 Therapeutic Impact of Immune Responses in Cancer